Skye Bioscience to Present at J.P. Morgan Healthcare Conference
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company will deliver a corporate overview on Thursday, January 16, 2025, from 10:30 AM to 11:10 AM. Interested parties can access both live and archived versions of the presentation through Skye's website.
Skye Bioscience (Nasdaq: SKYE), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento dell'obesità e dei disturbi metabolic, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. L'azienda offrirà una panoramica aziendale giovedì 16 gennaio 2025, dalle 10:30 alle 11:10. Le parti interessate possono accedere sia alla versione dal vivo che a quella registrata della presentazione attraverso il sito web di Skye.
Skye Bioscience (Nasdaq: SKYE), una empresa biofarmacéutica en etapa clínica especializada en el tratamiento de la obesidad y trastornos de salud metabólica, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. La compañía realizará una presentación corporativa el jueves 16 de enero de 2025, de 10:30 AM a 11:10 AM. Las partes interesadas pueden acceder a versiones en vivo y archivadas de la presentación a través del sitio web de Skye.
Skye Bioscience (Nasdaq: SKYE), 비만 및 대사 건강 장애 치료에 전문화된 임상 단계의 생명공학 회사가 제43회 연례 J.P. Morgan Healthcare 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 2025년 1월 16일 목요일 오전 10:30부터 11:10까지 기업 개요를 발표할 예정입니다. 관심 있는 분들은 Skye의 웹사이트를 통해 실시간 및 아카이브된 프레젠테이션에 접근할 수 있습니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise biopharmaceutique en phase clinique spécialisée dans le traitement de l'obésité et des troubles de la santé métabolique, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. L'entreprise fera un exposé sur ses activités jeudi 16 janvier 2025, de 10 h 30 à 11 h 10. Les parties intéressées peuvent accéder à la présentation en direct ainsi qu'à celle archivée via le site web de Skye.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Adipositas und Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt gegeben. Das Unternehmen wird am Donnerstag, den 16. Januar 2025 von 10:30 Uhr bis 11:10 Uhr eine Unternehmenspräsentation halten. Interessierte können sowohl die Live- als auch die Archive-Version der Präsentation über die Website von Skye abrufen.
- None.
- None.
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025, at 10:30 AM - 11:10 AM.
A live and archived webcast will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: statements regarding our product development, statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, statements relating to any expectations regarding the safety, including lack of neuropsychiatric effects, efficacy, tolerability or dosing of nimacimab, including based on preclinical models and the clinical information from the nimacimab Phase 1 study in NAFLD, statements regarding the ability of nimacimab to treat obesity or related indications, statements regarding the timing of receipt of interim and final data from Skye’s Phase 2 obesity study of nimacimab and statements regarding the therapeutic potential of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience (SKYE) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Skye Bioscience's J.P. Morgan Healthcare Conference presentation?
What is the focus of Skye Bioscience's (SKYE) therapeutic research?
Which annual J.P. Morgan Healthcare Conference will Skye Bioscience present at in 2025?
